<DOC>
	<DOCNO>NCT02630888</DOCNO>
	<brief_summary>The main goal study evaluate efficacy memantine association treatment previous combination two drug , include quetiapine lithium quetiapine aripiprazole young patient bipolar disorder type 1 non-responders partial responder combination drug evaluate impact association cognitive functioning patient .</brief_summary>
	<brief_title>Efficacy Memantine add-on Treatment Bipolar Disorder ( Type I ) Nonresponders Partial Responders Patients</brief_title>
	<detailed_description>Current evidence suggest deregulation brain glutamatergic neurotransmission involve pathophysiology bipolar disorder drug intervene transmission may therapeutic weapon address symptom cognitive deficit pathology . Among drug , particularly memantine strong candidate view efficacy antagonize N-methyl-D-aspartate ( NMDA ) receptor , good safety tolerability profile . The principal aim study evaluate efficacy memantine association treatment combination two drug , include quetiapine lithium quetiapine aripiprazole young patient bipolar disorder type 1 non-responders partial responder evaluate impact association cognitive functioning patient . An experimental study , randomize , double-blind , bipolar patient type 1 , sex , age 18 40 , ambulatory hospitalize , stage disease , seek treatment Mood Disorders Program ( GRUDA ) Institute o Psychiatry ( IPq ) Sao Paulo University ( FMUSP ) . Patients come ARIQUELI Project ( Missio , G. et al , 2013 submit Trial registration - ClinicalTrials.gov Identifier : . NCT01710163 ) . The study conduct two stage : I - initial administration memantine placebo 8 week ; II - Maintenance administration 4 month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 ) Partial responder nonresponders ( HAMD score &gt; 7 point and/or YMRS &gt; 9 point ) ARIQUELI Study ( quetiapine + lithium quetiapine + aripiprazole combination ) . EXCLUSION CRITERIA : 1 . Patients Schizophrenia , Schizoaffective Disorder Mental Retardation ( Intellectual Quotient Total le 90 ) ; 2 . Patients severe , unstable disease , include kidney disease , gastroenterology , respiratory , cardiovascular , endocrine , neurological , immunological haematological ; 3 . Hypo hyperthyroidism uncorrected ; 4 . Angleclosure glaucoma ; 5 . Changes blood coagulation use regular anticoagulant ; 6 . Patients serious risk suicide ( accord clinical criterion / score &gt; = 4 HAMD item suicide ) may participate study inpatient ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Memantine</keyword>
	<keyword>Lithium</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Cognitive effect drug</keyword>
</DOC>